NantHealth, CHOP, and their collaborators intend to release genomic, transcriptomic, and proteomic data from 1,600 patients in the next six months
BC Cancer Agency researcher Marco Marra presented preliminary lessons from a cancer genome- and transcriptome-based trial underway in the province.
The partners will exchange all information they have on genetic mutations leading to cancer with an eye toward accelerating research and drug discovery efforts.
The grant from St. Baldrick's Foundation will be used to support UCSC's genomics and informatics Treehouse Childhood Cancer Initiative.
The protocol is currently being used to study Tecentriq and Cotellic in children, but Genentech wants to use it to evaluate drugs across its oncology portfolio.
The laboratory will employ dedicated computational biologists and bioinformaticians to analyze genomic datasets for ALSF-funded researchers and other scientists.
FedCentric also plans to offer a combined hardware and software solution as well as a cloud-based software option for genomics customers.
The researchers plan to enroll 400 patients in the pilot, with the goal of increasing the availability of targeted therapies to pediatric cancer patients.
Cavatica is a project of CHOP's Center for Data Driven Discovery in Biomedicine and is part of its commitment to the Precision Medicine Initiative.
The consortium will focus on using molecular profiling technologies to enroll pediatric cancer patients in immunotherapy clinical trials.
The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.
The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.
New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.
In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.